RANI logo

RANI
Rani Therapeutics Holdings Inc - Ordinary Shares Class A

2,117
Mkt Cap
$132.45M
Volume
621,749.00
52W High
$3.87
52W Low
$0.387
PE Ratio
-2.62
RANI Fundamentals
Price
$1.07
Prev Close
$1.07
Open
$1.07
50D MA
$0.9763
Beta
1.68
Avg. Volume
903,189.52
EPS (Annual)
-$0.4486
P/B
3.76
Rev/Employee
$23,000.00
$52.20
Loading...
Loading...
News
all
press releases
Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday
Rani Therapeutics (NASDAQ:RANI) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-rani-therapeutics-holdings-inc-stock...
News Placeholder
More News
News Placeholder
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company...
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Lake Street Capital
Lake Street Capital initiated coverage on Rani Therapeutics in a research report on Tuesday. They set a "buy" rating and a $9.00 price target on the stock...
News Placeholder
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company...
News Placeholder
Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00
Canaccord Genuity Group lowered their target price on Rani Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday...
News Placeholder
Equities Analysts Offer Predictions for RANI Q1 Earnings
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rani Therapeutics in a report issued on Friday, March...
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Given "Buy" Rating at HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Rani Therapeutics in a research report on Friday...
News Placeholder
Rani Therapeutics Q4 Earnings Call Highlights
Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a transformational 2025 during the company's fourth-quarter and full-year earnings call, pointing to progress advancing...
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results
Rani Therapeutics (NASDAQ:RANI - Get Free Report) posted its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The...
News Placeholder
Rani Therapeutics (RANI) Expected to Announce Earnings on Monday
Rani Therapeutics (NASDAQ:RANI) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-rani-therapeutics-holdings-inc-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available